Press Releases

Date	Title	PDF Version
Sep 24, 2018	Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Sep 07, 2018	Alexion to Present at Morgan Stanley’s 16th Annual Global Healthcare Conference
Aug 29, 2018	Alexion to Present at Citi’s 13th Annual Biotech Conference
Aug 20, 2018	FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the US
Jul 26, 2018	Alexion Reports Second Quarter 2018 Results
Jun 28, 2018	Alexion to Report Second Quarter 2018 Results on Thursday, July 26, 2018
Jun 28, 2018	Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the European Union (EU)
Jun 19, 2018	Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S.
Jun 14, 2018	Alexion Announces Selection of Positive Phase 3 Clinical Data for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) for Late-Breaking Oral Presentation at Annual Conference of the European Hematology Association (EHA)
Jun 11, 2018	Alexion and Complement Pharma Announce Partnership to Co-Develop Pre-Clinical Complement Inhibitor for Neurodegenerative Disorders

Search